AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie elahere (mirvetuximab soravtansine) — Worldwide reported growth YoY (%) (%)
Form 8-K Key Product Revenues Schedule
Latest, FY2025
44.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04)
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Elahere (mirvetuximab soravtansine) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 44.0% | – | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
Cite this data
StockData. (2026). AbbVie Elahere (mirvetuximab soravtansine) — Worldwide reported growth YoY (%) (%), annual FY2025–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/elahere_ww_rep_yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.